Clinical Trial

Prolactin, Inflammation, and Parkinson's Severity

Study acronym: PRIPS

Enrolling by Invitation

Record status

This record was last updated September 9, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

Summary

This cross-sectional observational study aims to evaluate the relationship between serum prolactin levels, peripheral inflammatory markers (NLR, PLR, SII, CRP), and disease severity in patients with Parkinson's disease (PD). A total of at least 300 patients diagnosed with idiopathic PD will be included. Disease severity will be assessed using the Unified Parkinson's Disease Rating Scale (UPDRS) and the Modified Hoehn-Yahr staging system. Serum and salivary prolactin levels will be measured using ELISA, while inflammatory markers will be calculated from routine blood tests. The study seeks to clarify whether prolactin and systemic inflammation indicators may serve as non-invasive biomarkers for disease progression and prognosis in PD, with particular emphasis on postmenopausal women.

Trial Details

NCT Number	NCT07163156
Lead Sponsor	Çanakkale Onsekiz Mart University
Conditions	Idiopathic Parkinson Disease, Prolactin, Prolactin Levels, Inflammation
Enrollment	300 participants
Start Date	2025-08-14
Primary Completion	2025-12 (estimated)
Study Completion	2026-06 (estimated)
Updated on ClinicalTrials.gov	2025-09-09